HealthRX.com · Printable titration log
Mounjaro dose-step and weight-pace log with gallbladder check-ins
Record each dose step, the weight change week to week and any pain after meals, so you and your prescriber can see whether weight is coming off faster than the pace that diet studies tie to gallstones. The biology behind the page is summarised beside the log.
Where you started
Date Mounjaro started
Starting weightkg or lb, and keep to one unit
Past gallstones, sludge or gallbladder attacks?
Gallbladder already removed?
Other medicines and supplements
Weekly log
Weigh on the same day each week, at the same time of day.
| Week | Mounjaro dose (mg) | Weight | Change since last week | Skipped meals or very low-fat days | Upper-right pain after meals? | Note for the prescriber |
|---|---|---|---|---|---|---|
The biology in four lines
- Diet studies pooled by Weinsier and colleagues showed gallstone risk rising sharply at weight loss above 1.5 kg (about 3.3 lb) a week.[1]
- NIDDK: losing weight quickly or going long periods without eating makes the liver release extra cholesterol into bile, and fast weight loss can stop the gallbladder emptying properly.[2]
- In healthy volunteers, maximum gallbladder emptying under CCK was 28.79% after a single dose of exenatide, a GLP-1 drug, against 46.13% after placebo.[3]
- In pooled tirzepatide trials, gallbladder or biliary disease was more common than with comparators (RR 1.52), and the risk did not rise with dose.[4]
For the dose-step visit
- Is my weekly weight loss faster than you want while the dose is still going up?
- With my gallbladder history, would you check with an ultrasound first?
- Which symptoms should make me call before the next injection?
- Is ursodiol worth discussing in my situation?
Call rather than log
- Upper stomach pain, fever, yellowing of the skin or eyes, or clay-colored stools: tell your healthcare provider right away (Mounjaro Medication Guide).[5]
Sources for the facts on this sheet
- Weinsier RL, Wilson LJ, Lee J. Medically safe rate of weight loss for the treatment of obesity: a guideline based on risk of gallstone formation. Am J Med 1995. PMID 7847427. https://pubmed.ncbi.nlm.nih.gov/7847427/
- National Institute of Diabetes and Digestive and Kidney Diseases. Dieting & Gallstones. Accessed 2026-10-19. https://www.niddk.nih.gov/health-information/digestive-diseases/gallstones/dieting
- Keller J, Trautmann ME, Haber H, et al. Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects. Regul Pept 2012. PMID 22960288. https://pubmed.ncbi.nlm.nih.gov/22960288/
- Gong J, Gao F, Jiang K, et al. Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A meta-analysis. J Diabetes Investig 2025. PMID 39569606. https://pubmed.ncbi.nlm.nih.gov/39569606/
- Eli Lilly and Company, via DailyMed. Mounjaro (tirzepatide) injection, for subcutaneous use: prescribing information and Medication Guide. Effective 2026-08-27. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
This sheet records information for a conversation with your prescriber or pharmacist. It does not replace their instructions or the medication's prescribing information.